Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• the present invention deals with novel chemical conjugates for the selective delivery of cytotoxic drugs to tumor cells, and with methods of destroying tumor cells using such conjugates.
• antimitotic drugs such as adriamycin, vincristine, cisplatin, daunomycin and metiiothrexats, which all have strong undesirable side-effects on the normal cells of the patient. It is therefore Important that the activity of antitumor drugs be specifically directad to the malignant cells and have little toxic effect on the normal cells.
• the antibody may be radiolabeled, or it may be conjugated to toxins such as hematoporphyrin, abrin, ricin, diphtheria toxin, Pseudomcnas exotoxln, gelonin or to the above- mentioned antimitotic drugs.
• toxins such as hematoporphyrin, abrin, ricin, diphtheria toxin, Pseudomcnas exotoxln, gelonin or to the above- mentioned antimitotic drugs.
• toxins such as hematoporphyrin, abrin, ricin, diphtheria toxin, Pseudomcnas exotoxln, gelonin or to the above- mentioned antimitotic drugs.
• Another approach is to attach the drug to a polyaminoacid carrier which reduces Its cytotoxic action in normal cells.
• This carrier may bear a large number of drug molecules.
• the amino acid composition or sequence is intended to provide preferential release of the cytotoxin at tumor cells by means of degradative enzymes known to be present in elevated concentrations in tumor cells.
• degradative enzymes known to be present in elevated concentrations in tumor cells.
• a tumor-directed antibody and a degradable polyaminoadd carrier with a cytotoxic drug has also been described.
• Kato, et al., (1984), J. Medicinal Chem. 27, 1602-1607 reports conjugation of daunofmycin (DM) to polygiutamic acid (PGA) and coupling the resulting cytotoxic polymer with rat alpha fetoprotein (AFP) antibody.
• DM daunofmycin
• PGA polygiutamic acid
• AFP rat alpha fetoprotein
• the cytotoxic activity of the resulting anti-AFP-PGA-DM conjugate was shown to be more effective than nlg (a control antibody), anti-AFP, unconjugated DM, PGA-OM or nlg-PGA-DM.
• EP-A 112,720 discloses a conjugate comprising an immunoglobulin capable of binding selectively to a particular antigen possessed by a cell to be killed, a polymer carrier and a cytotoxic substance linked thereto, for instance p-(N,N-bis(2-Chloroethyl))-phenylenediamine, melphalan, 1-(beta-D-arabino-furancsyl) cytosine and its phosphate, methotrexate, actinomycin D, mltomycin C and the like, while Runge, US 4,485,093 discloses an immunotoxln conjugate for treating malignant diseases, which consists of arsanilic acid and tumor specific antibody covalently bound to a polygiutamic acid back-bone.
• polyaminoacid carrier does not solve all of the problems associated with the use of immunotoxins.
• addition of such carriers to antibodies, or even smaller Fab fragments may undesirably further reduce their ability to penetrate tumors efficiently.
• Pastan US 4,545,985 suggested conjugating Pseudcmonas exotoxin (PE) to a variety of peptides, proteins and growth factors that react with specific receptors on cells, including sarcoma growth factors, melanocyte stimulating hormone, somatostatin, glucagon, insulin, transferrin, low density lipoprotein (LDL), calcitonin, alpha-2-macroglobulin and lysine bradykinin, Pastan constructed a conjugate of Pseudomonas exotoxin (PE) and a peptide hormone isolated from mice, Epidermal Growth Factor (EGF) , by introducing thiol groups Into each and then linking the two using a dlsulfide exchange reaction. The conjugate was toxic to KB tumor cells, but nude mice Injected with the conjugate died of liver failure. The coupling destroyed the toxin's ability to bind to its own receptor, so toxicity was mediated by the EGF receptors
• JP 60163824 discloses a drug carrier, wherein the carrier comprises a protein, such as an apolipoprctein obtained from a serum lipoprotein (e.g., LDL). and a lipid, designed for selectively carrying the pharmaceutical ingredient to the necessary tissue.
• a protein such as an apolipoprctein obtained from a serum lipoprotein (e.g., LDL).
• a lipid designed for selectively carrying the pharmaceutical ingredient to the necessary tissue.
• toxin molecules that may be directly attached, as taught above, to a molecule of a peptide hormone or growth factor is limited by the need to preserve receptor binding activity. Furthermore, such conjugates of a non-immunoglobulin and a cytotoxin may be excessisvely toxic for normal cells bearing the appropriate receptors.
• the invention resides in destroying tumor cells with a novel drug conjugate comprising:
• a first moiety "a homing agent", a non-immunoglobulin which preferentially binds to a tumor cel l receptor, and is internalized by the cel l , and
• a second moiety covalently linked to the first moiety, and comprising a biodegradable polymeric carrier to which one or more cytotoxic molecules are attached.
• the degradation of the carrier by Intracellular enzymes releases a cytotoxic agent, resulting in destruction of the cell.
• the first moiety besides specifically binding to the tumor cell, also promotes the internalizatlon of the conjugate by that cell. It is also desirable that the carrier be particularly susceptible to tumor cell-associated intracellular enzymes in order to increase the therapeutic index of the conjugate.
• the homing agent is preferably a peptide or protein growth factor.
• One particularly preferred class of homing agent includes incuse Epidermal Growth Factor, and other related growth factors, such as human EGF (urogastrone), alpha transforming growth factor (TGF alpha), and vaccinia virus growth factor, which bind preferentially to tumor cells bearing EGF- bindlng receptors and are efficiently internalized by those receptors.
• the growth factor may be purified from natural sources, synthesized by stepwise peptide synthesis, or isolated from cells genetically engineered to express the factor.
• the agent may be a naturally occurring factor, a synthetic duplicate of that factor, or an active analogue or fragment of the factor, It may also be a substance which is a "pro" form of the factor, which the subject's body converts into the active form of the factor.
• a cytotoxic agent linked to TGF alpha should be selectively toxic to these tumors, not only because of the receptor-mediated uptake of the agent, but also because the mitogenic action of the growth factor should induce increased susceptibility to antimitotic drugs.
• the homing agent can render cells which carry receptors more sensitive to drug killing action after it has entered the cells.
• PGF Platelet-Derived Growth Factor
• PDGF Platelet-Derived Growth Factor
• PDGF is a dimer composed of two related peptides, each with a MW of about 30,000 D, which is released from platelet granules when blood clots form. It is required by smooth muscle cells, fibroblasts and other mesenchymal cells, but not by- epithelioid or hematopoetic cells (Cochran and Stiles, (1983), Cell 33, 939-347). After binding to receptors on a cell, PDGF is Internalized [Nilsson et al., (1983), Proc. Natl. Acad.
• a fusion protein containing 80 amino acids of the SV40 t antigen fused to the amino terminus of one chain of PDGF was active in internalIzatlon [Wang and Williams, (1984), J. Bio. Chem. 259, 10645-10648], indicating that PDGF, like EGF, could be expected to carry material preferentially into cells bearing appropriate receptors.
• PDGF is also known to be produced by some tumor cells in culture, including glioma, osteosarcoma, embryonal carcinoma, and a variety of neoplastically transformed fibroblasts [Van Zoelen et al., (1985), Mol. Cell. Biol. 5, 2289-2297], which suggests a possible self-stimulatory role like that postulated for TGF alpha.
• PDGF may be useful for homing and internalization of cytotoxic conjugates of the invention into these tumors.
• NGF Nerve Growth Factor
• Transferrin could also be used as a homing agent to deliver cytotoxic drugs to tumors because, like EGF, transferrin-receptor complexes are internalized [Karin and Mintz (1981) J. Biol. Chem 256: 324-3252]. O'Keefe and Draper, (1985), J. Biol. Chem., 260, 932-937, reported that toxicity of a transferrin-diphtheria toxin conjugate was abolished in the presence of excess transferrin, which indicates that this conjugate was internalized via transferrin receptors. As disclosed by Pastan (US 4,545,985), antibodies to the transferrin receptor can be used to deliver toxins to tumors, particularly adult T cell leukemia. Transferrin is also used in radioimaging of tumors [NTIS Tech Note, (1985), NTN85-0891], which Indicates preferential binding of tranferrin to these tumors.
• alpha melanocyte-stimulating hormone (alpha MSH), another small peptide hormone, was genetically fused to a cytotoxic protein, and the fusion protein reportedly was cytotoxic for melanoma cells [Murphy, et al., (1986), Proc. Nat, Acad, Sci., USA, 83, 8258-8262].
• TRH thyrotropin-releasing hormone
• TRH tripeptlde
• the following desiderata should be considered: a) the homing substance must be highly specific for tumor cells, as opposed to normal cells; b) the homing substance should bind to a receptor found fn a wide range of tumor cells; c) the homing substance should promote the internal ization (receptor interaction) of the conjugates; d) the homing substance should stimulate cell proliferation and/or metabolism, therefore rendering the targeted cell more vulnerable to antimitotic or other antimetabolic action of the cytotoxin; e) the homing substance should be sufficiently small to penetrate solid tumors efficiently; f) suitable chemistry must exist for coupling the cytotoxic compound carrier to the homing agent.
• the second moiety in the conjugate of the invention is a polymeric carrier for the cytotoxic agent and comprises a plurality of repeating units, each unit having the structure shown in formula (I) below:
• p is preferably 1 or 2
• x is preferably in the range of 0-20
• A is a linker, preferably an amino acid, and where, if x is greater than 1, the amino acids A x may be the same or different.
• T is either hydroxyl or a cytotoxic substance.
• the units may be identical, or they may vary in p, x, A x , or T. Of course, for the conjugate to have a cytotoxic effect, at Teast one of the units must bear a cytotoxic molecule.
• the conjugate per se is preferably of reduced cytotoxlcity to normal cells as compared to the substance T in its free form. Intracellular release of T in cytotoxic form is accomplished by cellular enzymes, preferably enzymes preferentially expressed in tumor cells.
• a x where A may vary among the common amino-acids, and x is preferably in the range 0-20, involves the usual techniques of peptide synthesis. It is assumed that the preferential manifestation in malignant cells of the cytotoxlcity typical of the free cytotoxic substance is a function of intracellular enzymatic degradation of the conjugate, liberating either the cytotoxic substance or active derivatives thereof. Preferential release within malignant cells may thus be governed by a di fferential in terms of type or enhanced level of enzymatic activity between malignant and normal cells.
• such enzymatic cleavage at the polygiutamic add ⁇ -carboxyl, or general proteolytic cleavage within A x or of the polygiutamic acid polymer backbone may release a peptidyl prodrug of the cytotoxic substance subject to further processing by lysosomal enzymes, and involving the ⁇ -glutamyl transferase when the drug is ⁇ -linked to glutamic acid in A x .
• the extent and rate of endocellular drug release may thus be significantly affected by variation in the length and nature of the A x moiety.
• Such processing by lysosomal enzymes of bovine serum albumin-daunomycin conjugate has been shown by A. Trouet, et al. [(1982), Proc. Natl. Acad. Sci., 79, 626; and (1980), J. Med. Chem., 23, 1166-l171] to vary widely with the length and sequence of the peptide moiety interspersed between the protein and the drug.
• the cytotoxic substance is selected from agents inhibitory of DNA synthesis and function (e.g., adriamycin, daunomycin, bleomycin, melphalan, chlorambucil, cisplatin), of microtubule (mitotic spindle) formation and function (e.g., vinblastine, vincrfstlne), or antimetabolites (e.g., methotrexate), or cytotoxic substances of these or other mechanisms of action.
• agents inhibitory of DNA synthesis and function e.g., adriamycin, daunomycin, bleomycin, melphalan, chlorambucil, cisplatin
• microtubule (mitotic spindle) formation and function e.g., vinblastine, vincrfstlne
• antimetabolites e.g., methotrexate
• At least 10 percent of the units of formula (I) bear a cytotoxic agent (not necessarily the same one for all units). However, higher levels of substitution are preferred unless they significantly reduce the cytospecificity of the conjugate.
• the number of repeating units is not fixed, but is preferably in the range of 20-300.
• the MW of the polymeric carrier is preferably high enough so that, even If it becomes detached from the homing substance before entering tumor cells, it does not freely enter cells lacking receptors for the homing agent, by passive mechanisms; but rather it should only enter cells actively, by receptor-mediated endocytosfs.
• the polymeric character of the drug construct should prevent its penetration of heart tissue, mitigating against a major shortcoming of daunomycin and other aniitumor drugs.
• the preferred molecular weight (MW) of the total conjugate 1s in the range of 10,000 to 100-0000, and less than 50,000 is especially preferred.
• the MW of the conjugate must be low enough so that it may penetrate solid tumors efficiently. It is known that Fab fragments of antibodies penetrate tumors better than the intact antibodies. [See Delabye, et al., (1986), J. Clin. Invest. 77: 301-11; Buchegger, et al. (1983), J. Exp. Med 158: 413-27; Buchegger et al.
• IgG antibodies have MWs of about 150,0000 prior to addition of any carrier molecules, and even Fab fragments, which are somewhat smaller, may be still be unable to penetrate tumors efficiently after conjugation with a carrier.
• the prepared conjugates of the invention typically had a total MW of about 46,000 D, where the EGF is about 6,000 D and the polymer contributes most of the remaining 40,000 D.
• Free daunomycin has a MW of about 5000, so several moles could be attached to each conjugate while maintaining the preferred MW range.
• homing agent and polymeric moieties are conjugated either directly by peptide linkage, a secondary amide linkage of amino-acids, as in peptides and proteins, or, preferably, by a bridging unit of formula:
• R 1 derives from a heterobi functional reagent of formula:
• alkylene (C 1 -C 4 ), preferably (C 3 ); phenylene, preferably (1,3-); cycloalkylene-alkylene, preferably cyclohexylene-4-methylene; or alkylene_phenylene, preferably alkylene (C 1 - C 4 ) -phenylene (1,4); and where Y H or SO 2 ONa.
• Other heterobifunctional reagents differentiating reactive functions of the homing agent and polymeric moiety may also be employed.
• the therapeutic conjugate of the present invention is a conjugate of EGF with a polygiutamic acid carrier bearing one or more molecules of daunomycin.
• a conjugate should offer three fold specificity: (a) specificity for tumor cells having high concentrations of EGF receptors, since these will more effectively bind and internalize the conjugate
• conjugates which bind to all tumor celts and to no normal cells may still show sufficient specificity for tumor cells to be of therapeutic activity.
• the targeting agent of the conjugate also promotes internal ization, it is conceivable that these functions could be performed by different moieties.
• Figure 1a is a photomicrograph of a culture of A431 human squamous carcinoma cell line used to test the effect of the compounds of the invention. The presence of large amounts of EGF receptors thereon 1s indicated by Indirect immunoperoxidase staining (dark color).
• Figure 1b is a photomicrograph similar to that of Figure 1a, but of a culture of normal WI38 embryonic fibroblast cells used as a control. The low level of EGF receptors is indicated by the near absence of staining (light color).
• Figure 2a is a photomicrograph of an A431 cell line culture after a 48-hour incubation of 1 ⁇ q/ml of free daunomycin and testing for dead cells with Trypan Blue exclusion dye.
• Figure 2b is a photomicrograph similar to that of Figure 2a, but after 48-hour incubation with, instead, 1 ⁇ q/ml of daunomycin in the form of conjugate VIII.
• the dark areas represent the killed cells.
• Figure 3a is a photomicrograph at time zero of a mixed culture of A431 and WI38 cell lines.
• the round cells are the tumor cells.
• Figure 3b is a photomicrograph similar to that of Figure 3a showing the situation after 43-hour incubation with 1 ⁇ q/ml of conjugate VIII. The round tumor cells have greatly diminished.
• the preferred new therapeutic compounds of the invention, using EGF or analogs as homing vector are of formula II:
• T may vary in p, x, A x , or T, with T being a cytotoxic substance in at least one of the units.
• EGF a single polypeptlde of 53 amino adds, can be extracted from submaxtllary glands of mice [see J. Savage et al., (1972) J. Biol. Chem. 247, 7609] or it can be synthesized chemically, or by genetic engineering methods, for example using a cloned gene. EGF can also be of human origin.
• the cytotoxic substance T and the A x moiety of formula II are normally covalently linked, the nature of the linkage dependent upon the functionality employed in the T and A x components.
• Primary amine functionality in the cytotoxic substance T is normally employed in secondary amide linkage with a terminal carboxyl of A x .
• the cytotoxic substance T may also be a cytotoxic platinum complex analogous to cisplatin.
• the co-ordinate linkage of platinum compounds by the polymeric carrier may be achieved by the utilization as ligand of the ⁇ - carboxy moiety of polygiutamic acid, or of amine or amino-acid or other ligand moieties incorporated in A x ; see Arnon, EP-A 190,464. 1
• R is a group deriving from a heterobifunctional reagent employed in the elaboration of the linkage conjugating the preferred homing agent EGF and the polymeric moiety III.
• the conjugation is effected by the coupling of an N-substituted EGF derivative IV:
• thiol-reactive compound IV is prepared by reaction of EGF with a heterobifunctional reagent VI:
• reagents conforming to this heterobifunctional character, which may be used for the generation of alkylating derivatives of EGF, are m-maleimid ⁇ benzoyl-N-hydroxysuccinimide ester, m-maleimidobenzoylsulfo- succinim ⁇ de aster, succinimidyl-4-(n-ntaleimidomethyl) cyclohexane-1- carboxylate, sucdnimidyl-4-(p-maleimido ⁇ henyl) butyrate, sulfosuccinimidyl- 4-(N-maleimidomethyl) cyclohexane-1-carboxylate, sulfosuccinimidyl -4-(p- maleimidophenyl) butyrate.
• the thiol-substltuted polymer V is prepared following Kato et al., (1984), J. Med. Chem., 27, 1602-7. In brief, this involves the generation of a thiol-masked polymer derivative VII: where m, n, p, x, and R 2 are as previously defined, and partial substitution of the polymer side chains with the cytotoxic substance T, followed by removal of the 2-pyridylthio masking group.
• n is 20-300
• p is 2, x 1s 0, R 1 1s (CH 2 ) 3
• R 2 is H
• T is daunomycin or hydroxyl in a ratio of about 1 to 6;
• n is 20-300
• p is 2
• x is 3
• a x is Gly-Gly-Leu
• R 1 is (CH 2 ) 3
• R 2 is H
• T is daunomycin or hydroxyl in a ratio of about 1 to 6
• side-chain extension A x where A may vary among the common amino-acids, and x is preferably in the range 0-20, involves the usual techniques of peptide. synthesis. [See, for examples, W.A.R. van Heeswijk, et al., (1985), J. Controlled Release 1, 301-315, and Hoes et al., (1985), J. Controlled Release 2, 205-213.]
• Compound II demonstrates very useful properties in cancer therapy.
• Compound II is internalized by malignant cells and the cytotoxlcity of the cytotoxic substance daunomycin is expressed therein. Its selectivity of action upon malignant cells is greater than that of known cytotoxic drugs.
• the first valuable property relates to its strong affinity toward malignant cells over normal cells.
• a human squamous carcinoma cell line was selected, for instance A431 cell line shown in Figure 1a [see M.D. Waterfleld (1982), J. Cell. Biochem., 20, 149-161], although other tumor cells can be used as well.
• the membrane of these cells contains a very large concentration of EGF receptors which makes them highly suitable for tests with Compound II.
• the presence of these receptors is shown by indirect immunoperoxidase staining and appears as dark color areas of Figure 1a.
• Control cell lines for instance WI38 embryonic fibroblast cells with a low amount of EGF receptors (see Figure 1b), were treated identically for comparison and appear as lighter color areas on the photomicrograph.
• Conjugate VIII As compared to free EGF is possibly due to retention of EGF by the polymer backbone of Conjugate VIII by endocytic vesicles, whereas EGF is recycled freely back to the medium.
• Application of tests for internal ization of a conjugate by appropriate receptor-bearing cells, such as that described in example 3, below, can be used to determine whether or net a the homing substance in a given conjugate has retained its capacity for internallzation, and, therefore, may be suitable for treatment of tumors.
• a second valuable and unexpected property of Compound II relates to Its enhanced toxidty as compared with free daunomycin toward malignant cells. This is illustrated by Figures 2a and 2b.
• FIG 2a a culture of A431 cells 1s shown after 48 hrs incubation with a medium containing 1 ⁇ q/ml of free daunomydn. Viability was scored by means of the Trypan Blue exclusion dye method. Exclusion of the dye from the cells demonstrates the viability thereof. In contrast, when an equivalent amount of daunomycin in the form of Conjugate VIII was used in a similar experiment (see Figure 2b), a very large number of cells were killed as shown by the shrivelled up cells and the dark areas where the dye has accumulated.
• figure 3a and 3b show the effect of Conjugate VIII in the case of a mixed culture of A431 and WI38 cells.
• the round cells represent the A431 tumor cells and the elongated cells are the WI38 control cells.
• the culture medium was photographed at time zero ( Figure 3a).
• Figure 3b Illustrates this situation after 24 hrs in a medium containing 1 ⁇ q/ml of Conjugate VIII. It can be seen that the round darker malignant cells have strongly regressed.
• Testing similar to that described in examples 4, 5 and 7, below, can be performed to determine the enhancement of selectivity and/or potency of any given cytotoxin for any selected tumor cells provided by any desired form of Compound I.
• Conjugate VIII was much more lethal to squamous carcinoma cells than free daunomycin itself. Also, Conjugate VIII has a selective mortal activity on tumor cells, but leaves normal cells alive, whereas under the same conditions, free daunomycin will kill normal cells.
• DTT dithiothreitol
• (DM)-Glu-SH The poly-(DM)-Glu-SH polymer was reacted with an excess of thlopropyl-SEPHAROSE in the pyridylsulflde form (4° C; 12 hrs; phosphate buffer, pH 6) and the gel was rinsed with an excess of the same buffer in order to eliminate the polymer lacking the SH extremity. The polymer was conserved In this form in the cold. It was then regenerated by treating the gel with an excess of mercaptoathanol (12 hrs), dialyzed against water
• EGF EGF
• 10 mM phosphate buffer, pH 7.0, containing 0.14 M NaCl 10 mM phosphate buffer, pH 7.0, containing 0.14 M NaCl.
• a quantity of 125 I-EGF sufficient to provide an activity of 10,000 cpm/ ⁇ g EGF was added followed by
• the gel was washed successively with 3 portions of 1 ml of sodium phosphate buffer, the eluent was concentrated under reduced pressure and subjected to gel filtration on SEPHADEX G75 (column 40 x 0.8 cm), using 0.1 M ammonium carbonate solution, pH 7.0.
• Indirect imrnunoperoxidase staining on cell lines were performed on trypslnized cells in 35 mm PVC plates.
• the surface was pre-treated with phosphate buffered saline (PBS) pH 7.2, the excess was then removed and the PBS washed cells (10 5 /well in 50 ⁇ l PBS) were added to the plated and centrifuged for 5 minutes at 2000 rpm. 50 ⁇ l/well of 0.5 percent glutaraldehyde in cold PBS were then added to the dish and incubated for 15 minutes at room temperature.
• PBS phosphate buffered saline
• the in situ coloring was achieved by incubating the cells at room temperature with a solution of 10 ml 0.01 M phosphate buffer, pH 6.0, 5 ⁇ l, 35 percent oxygenated water and 100 ⁇ l of 1 percent ortho-dianisidln (MERCK) in methanol.
• the Conjugate VIII radiolabeled with 125 I on the EGF, was incubated with confluent cell cultures of A431 and WI38 cells for 6 hrs at 37° C in solution A (4 parts DMEM and 1 part of 50 mM Tris, 100 mM NaCl and 0.1 percent BSA adjusted to pH 7.4). The cells were then washed four times with ice- cold PBS + 1mM CaCl 2 and 1 mM MgCl 2 - Fifty percent trichlcracetlc acid was added in a proportion of 1:5 to the pooled solution A and PBS, and the mixture was counted on a gamma counter.
• the cel l membrane was destabUzed by treatment on ice with 200 mM acetic acid and 150 mM NaCl (solution B) for 6 minutes. The solution B was then removed and the cells washed twice with solution B. These pooled B solutions were assayed for 125 I. This treatment releases the EGF receptors bound to the cell surface. The cells were then completely dissolved in 0.2 N NaOH. The radioactivity found there represented the interalized Conjugate VIII. In control experiments, using free EGF 125 I, a proportion of the EGF is recycled to the medium, therefore lowering the intracellular EGF.
• DMEM Dulbecco's Modified Medium
• FSC foetal calf serum
• Ibco penicillin-streptomycin
• fungizone GIBCO
• VI polymeric compound
• the polymer was subjected to the procedure reported by Hesswijk, et al., (1985), J. of Controlled Release, 1 (4), 312, for extending the side chain with -Gly-Gly-Leu- (A x in formula II), as follows: 40 mg of the polymer and 68mg of saccharin (0.31 mmole) were dissolved in 1 ml of DMF and the solution was allowed to stand for a few hours (solution A).
• the pyridine-S group was removed with dithiothreitol according to Kato, et al., and analysis was performed by measuring the absorbance at 343 nm of the liberated pyridine-2-thione. Neglecting the presence of the TMG+ ion, a MW of 25,500 was found, meaning that in the product the degree of polymerization is about 75-80.
• daunomycin was accomplished as follows: 33.7 mg (74.7 umole) of the side-chain extended polymer were dissolved in 15ml of 2 percent aqueous NaCl and 20 mg (35.5 ⁇ mol e) of daunomycin hydrochloride were added. The pH was brought to 5.5 with 0.1 N NaOH after which 28 mg (0.1 mmole) of 1-ethyl-3-[3-(dimethylamino)]-carboiimide hydrochloride (EDC) were added under stirring.
• EDC 1-ethyl-3-[3-(dimethylamino)]-carboiimide hydrochloride
• the overall volume of both the dialyzed polymer and dialyzed EGF solution were reduced to 1 ml by absorption with CMC powder, then they were mixed together and allowed to stand for 24 hrs in one dialysis bag.
• the mixture was chromatographed on SEPHADEX G75 (eluent 0.1M NH 4 CO 3 ) and the fractions absorbing at 430 nm were collected and cleaned from unreacted polymer by treating with thiopropylsepharose overnight at 4° C.
• the gel was washed with 0.1M NH 4 CO 3 and 22.5 ml (O.D. of 0.176) of solution was collected. Yield was about 80 percent of Conjugate IX.
• the respective weight contributions of DM and EGF in the product are about equal.
• BSA was added to 12 ⁇ l of a solution of antiserum against EGF (Collaborative Research) so as to provide a 0.3 percent by weight BSA solution in antiserum (Ab).
• Both (S) and (Ab) were Incubated overnight at 4° C, then a quantity of Conjugate IX corresponding to 120 ⁇ g of daunomycin was added to sample Ab and incubated for 7 hrs at 4° C under agitation. Then solution (S) was added and the mixture was agitated per 12 hrs at 4° C.
• a control (C) was prepared by adding the same quantity of Conjugate IX to another identical sample of solution (S).
• Cells were plated on 1.5 cm Petri dishes at 50 percent to 60 percent of confluence before the addition of the toxin. 0.1, 0.5 or 1 ⁇ q/ml doses of daunomycin (controls) or its equivalents in the form of Conjugate IX were added in DMEM 10 percent FCS. Cell death consecutive to this addition was measured as follows: the cells were exposed for 1 hour at 37° C in 500 ⁇ l DMEM low methlonine medium (GIBCO) containing radioactive 35 S met. The medium was then removed and the dishes were washed with PBS 9137 mM NaCl, 2.7 mM
• Example 8 In Vivo Test of Conjugate VIII
• 5 x 10 6 A431 cells nude mice and when the tumors reached 3 to 5 mm, we injected into two sets of nude mice 0.1 mg/kg of daunomycin either in the form of conjugate VIII (see example 1) or in free form.
• up to 10 mg/kg doses have been used in mice (S. Schwarz, et al., 1975, Cancer Chem. Rep., 6, 2, 107-114).
• the drug was injected either directly in the tumor or in the caudal vein 4 times at 3 days intervals. The measures were taken a week after the last injection.
• the compounds of the Invention show better performances in selectively killing squamous carcinoma cells than daunomycin, both in vitro and in vivo.
• very low amounts of conjugate VIII have a remarkable effect on tumor growth.
• Example 9 In Vivo Test of Conjugate IX The in vivo tests reported in Example 8 were repeated using Conjugate IX. Thus, 2 mg/kg of daunomycin, free or in the form of Conjugate IX were injected every 3 days over 9 days in the caudal vein of nude mice bearing A431 tumors. The tumor growth inhibition by conjugate IX was significantly greater than by free daunomycin (D), free EGF or DM labelled but untargeted polymer (DMA). These results are shown in the Table 5 below where the values correspond to tumor diameter (in mm) measured with a calliper after a number of days. The lethal dose of Conjugate VIII and Conjugate IX have not been measured but are presumably less toxic than free daunomycin which enters freely into most normal cells.
• D free daunomycin
• DMA DM labelled but untargeted polymer

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (2)

Family

ID=8196463

Family Applications (1)

Country Status (10)

Cited By (24)

Families Citing this family (286)

Family Cites Families (16)

• 1987
  • 1987-07-29 IN IN543/MAS/87A patent/IN165717B/en unknown
  • 1987-08-05 DE DE8787201490T patent/DE3770730D1/de not_active Expired - Fee Related
  • 1987-08-05 WO PCT/EP1987/000435 patent/WO1988000837A2/en active Application Filing
  • 1987-08-05 EP EP87201490A patent/EP0259904B1/en not_active Expired - Lifetime
  • 1987-08-05 JP JP62504770A patent/JPH01500435A/ja active Pending
  • 1987-08-05 AU AU77887/87A patent/AU608531B2/en not_active Expired - Fee Related
  • 1987-08-05 FI FI881579A patent/FI881579L/fi not_active IP Right Cessation
  • 1987-08-06 CA CA000543912A patent/CA1323303C/en not_active Expired - Fee Related
  • 1987-08-06 US US07/082,244 patent/US5087616A/en not_active Expired - Fee Related
• 1988
  • 1988-04-06 DK DK184788A patent/DK184788A/da not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events